Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Misses Expectations By $3.45 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings data on Thursday. The company reported ($5.71) EPS for the quarter, missing the consensus estimate of ($2.26) by ($3.45), FiscalAI reports. The company had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Phase 3 myelofibrosis readout in March 2026: Karyopharm expects top-line data from its frontline selinexor + ruxolitinib (CENTURY/SENTRI) trial next month, positioning the combo to be the first frontline combination and a potential major value driver if positive.
• Phase 3 endometrial cancer data mid‑2026: The EXPORT‑EC042 trial remains on track for mid‑2026 top‑line results, supported by promising long‑term SIENNA subgroup data in P53 wild‑type/pMMR patients that Karyopharm highlights as a meaningful expansion opportunity.
• Near‑term cash runway into Q2 2026: The company ended 2025 with ~$64.1M in cash and says existing liquidity funds operations only into the second quarter, and it is actively evaluating financing and strategic options to bridge to and beyond upcoming readouts.
• Commercial performance and 2026 guidance: Xpovio net product revenue grew to $114.9M in 2025, management expects $115M–$130M in 2026 and continues to position Xpovio in community and peri‑T‑cell engager settings as a durable commercial foundation.

Karyopharm Therapeutics Trading Up 25.5%

Shares of Karyopharm Therapeutics stock traded up $1.88 during trading hours on Thursday, reaching $9.25. 1,386,142 shares of the company’s stock were exchanged, compared to its average volume of 467,340. The stock has a market cap of $169.33 million, a P/E ratio of -0.64 and a beta of 0.21. The company has a 50 day moving average of $6.86 and a two-hundred day moving average of $6.18. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KPTI. Geode Capital Management LLC grew its stake in shares of Karyopharm Therapeutics by 101.2% in the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock valued at $1,382,000 after buying an additional 94,445 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $163,000. Bank of America Corp DE lifted its holdings in Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Karyopharm Therapeutics during the third quarter worth $164,000. Finally, XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics in the second quarter valued at $56,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KPTI has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. The Goldman Sachs Group set a $12.00 price objective on Karyopharm Therapeutics in a research report on Wednesday, December 17th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They set an “overweight” rating on the stock. Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.